Innoviva Price to Book Ratio 2006-2020 | INVA

Historical price to book ratio values for Innoviva (INVA) over the last 10 years. The current price to book ratio for Innoviva as of August 03, 2020 is 2.84.
Innoviva Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2020-08-03 13.81 2.84
2020-06-30 13.98 $4.86 2.88
2020-03-31 11.76 $4.01 2.94
2019-12-31 14.16 $3.38 4.19
2019-09-30 10.54 $2.80 3.76
2019-06-30 14.56 $2.44 5.98
2019-03-31 14.03 $1.98 7.10
2018-12-31 17.45 $1.57 11.09
2018-09-30 15.24 $-1.07 -14.22
2018-06-30 13.80 $-1.53 -9.03
2018-03-31 16.67 $-2.10 -7.94
2017-12-31 14.19 $-2.38 -5.96
2017-09-30 14.12 $-2.06 -6.84
2017-06-30 12.80 $-2.71 -4.72
2017-03-31 13.83 $-3.06 -4.52
2016-12-31 10.70 $-3.26 -3.29
2016-09-30 10.99 $-3.36 -3.27
2016-06-30 10.53 $-3.26 -3.23
2016-03-31 12.59 $-3.20 -3.93
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.399B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $387.947B 18.49
Roche Holding AG (RHHBY) Switzerland $302.429B 0.00
Pfizer (PFE) United States $213.028B 13.32
Merck (MRK) United States $208.339B 14.90
Novartis AG (NVS) Switzerland $191.450B 14.88
Novo Nordisk (NVO) Denmark $154.051B 25.66
AstraZeneca (AZN) United Kingdom $149.117B 28.99
Eli Lilly (LLY) United States $146.187B 22.31
AbbVie (ABBV) United States $141.679B 10.32
Sanofi (SNY) $133.245B 15.84
GlaxoSmithKline (GSK) United Kingdom $103.577B 13.58
Bayer (BAYRY) Germany $64.831B 9.24
H Lundbeck (HLUYY) Denmark $7.412B 12.88